NMEz-2881529 is under clinical development by ZYUS Life Sciences and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NMEz-2881529’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NMEz-2881529 overview
NME-z2881529 is under development for the treatment of neuropathic pain. It comprises of cannabinoid formulation. It acts by targeting CB1 and CB2.
ZYUS Life Sciences overview
ZYUS Life Sciences. (ZYUS) is a Canadian-based pharmaceutical company. It focuses on the development and commercialization of phyto-therapeutics, which includes protein-based formulations and cannabinoid. The company provides gel-caps, oils, topical creams and other cannabinoid-based therapeutics and product candidates for patients across Australia, Germany, Luxembourg, Canada and Portugal.
For a complete picture of NMEz-2881529’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
